Capital call

Tasked by the U.K. government with outlining a plan to grow its life sciences industry post-Brexit, John Bell has laid out aggressive goals for creating a sustainable biotech sector, and wants to see the country develop the infrastructure necessary to attract more public market participation and encourage long-term investors.

Bell believes the U.K.’s strength lies in the NHS’s wealth of patient data, which he thinks can propel the country to a leadership position in genomics-driven drug discovery and diagnostics...